Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesImmunology/RheumatologyAvMed Actimmune prior auth Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentAvMedPolicy Pub. 100-2

    Actimmune (interferon gamma-1b) prior authorization

    Customize your policy alerts

    Sign up for AvMed Policy Pub. 100-2 alerts

    Get alerted when Policy Pub. 100-2 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document governs prior authorization and step-edit requests for Actimmune (interferon gamma-1b) for AvMed members, specifying required prescriber signatures, clinical criteria for Chronic Granulomatous Disease and severe malignant osteopetrosis, and documentation needed for approval.

    Policy Summary
    PayerAvMed
    PolicyActimmune (interferon gamma-1b) prior authorization
    Policy CodePolicy Pub. 100-2
    Change TypeNo material changes
    Effective Date
    Last ReviewSep 16, 2019
    Next Review Date
    Key ActionSubmit a signed medical prior authorization/step-edit request form with required clinical documentation faxed to 1-877-535-1391.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2covered diagnoses listed
    1 yearlength of therapy
    J9216HCPCS code

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    SC thrice weeklyadministration frequency

    Coverage Criteria for Actimmune (interferon gamma-1b)

    Initial Therapy d

    Covered when ALL of the following are met for the selected diagnosis

    Prescriber must be appropriately specialized: Infectious Disease specialist or Hematologist for Chronic Granulomatous Disease (CGD); Endocrinologist or other specified physician for severe malignant osteopetrosis.

    checkbox on form

    Diagnostic confirmation for CGD: One of: Nitroblue tetrazolium test (Negative) OR Dihydrorhodamine test (DHR+ neutrophils < 95%) OR Genetic analysis/immunoblot positive for p22phox, p40phox, p47phox, p67phox, or gp91phox.

    checkboxes on form

    Prior prophylactic therapy for CGD: Documented trial and failure of prophylactic antimicrobials: trimethoprim/sulfamethoxazole (5 mg/kg daily, divided) AND itraconazole (200 mg/day for patients > 50 kg).

    documented trial and failure required

    Diagnostic confirmation for severe malignant osteopetrosis: Documentation of all of the following: X-ray or increased liver function tests; decreased RBC and WBC counts; growth retardation; and deafness/sensorineural hearing loss. PLUS baseline labs: CBC with differential, platelets, LFTs, electrolytes, BUN, creatinine, and urinalysis.

    checkboxes on form

    Administration and dosing: Injections administered subcutaneously three times weekly. Pediatric dosing: 50 mcg/m2 for patients with body surface area > 0.5 m2, and 1.5 mcg/kg/dose for patients with body surface area ≤ 0.5 m2. Length of therapy: ONE year.

    dosing and duration language on form

    Use of samples to initiate therapy does not meet step edit/preauthorization criteria. Providers should not rely on manufacturer or office samples as the start of therapy when submitting a prior authorization or step-edit request for Actimmune, because sample use will not satisfy the document requirements for prior authorization.

    Coding and Dosing Information

    Covered HCPCS CodesHCPCSCovered
    J9216Actimmune (interferon gamma-1b)
    Length of therapy
    Length of therapyONE year
    Administration frequencyInjections administered subcutaneously three times weekly
    Single-use vial noteA vial of ACTIMMUNE is suitable for a single use only
    Body surface area dosing threshold
    BSA > 0.5 m2 dosing50 mcg/m2 per dose
    BSA ≤ 0.5 m2 dosing1.5 mcg/kg per dose
    Dosing scheduleInjections administered subcutaneously three times weekly

    Provider Requirements and Prior Authorization Steps

    Prior Authorization

    Prior authorization required

    Prescribers must submit a signed medical prior authorization/step-edit request form faxed to 1-877-535-1391 with required clinical documentation to obtain authorization for Actimmune (J9216).

    Step Therapy

    Step therapy required for CGD

    For Chronic Granulomatous Disease (CGD), the form requires documented trial and failure of prophylactic antimicrobials — trimethoprim/sulfamethoxazole (5 mg/kg daily, divided) AND itraconazole (200 mg/day for patients > 50 kg) — before approval.

    Documentation Required

    Required documentation and prescriber signature

    Background

    Actimmune (interferon gamma-1b) is indicated for Chronic Granulomatous Disease (CGD) and severe malignant osteopetrosis per the prior authorization form. The form specifies that prescribers should be appropriately specialized (e.g., Infectious Disease or Hematology for CGD) and documents diagnostic confirmation and baseline testing before approval.

    Diagnostic Criteria and Definitions

    CGD diagnostic criteria
    Nitroblue tetrazolium testNegative
    Dihydrorhodamine (DHR) testDHR+ neutrophils < 95%
    Genetic/immunoblot evidencePositive for p22phox, p40phox, p47phox, p67phox, or gp91phox
    Severe malignant osteopetrosis diagnostic criteria
    Required diagnostic findingsDocumentation of all: X-ray or increased liver function tests; decreased RBC and WBC counts; growth retardation; deafness/sensorineural hearing loss
    Required baseline testingCBC with differential, platelets, LFTs, electrolytes, BUN, creatinine, and urinalysis
    Prescribing specialist
    Policy Summary
    PayerAvMed
    PolicyActimmune (interferon gamma-1b) prior authorization
    Policy CodePolicy Pub. 100-2
    Change TypeNo material changes
    Effective Date
    Last ReviewSep 16, 2019
    Next Review Date
    Key ActionSubmit a signed medical prior authorization/step-edit request form with required clinical documentation faxed to 1-877-535-1391.
    SourceLink
    On This Page
    Coverage Criteria for Actimmune (interferon gamma-1b)Coding and Dosing InformationProvider Requirements and Prior Authorization StepsBackgroundDiagnostic Criteria and Definitions

    Provide a hand-signed prescriber signature and supporting documentation for every clinical criterion checked on the form, including lab results, diagnostic test results, chart notes, and baseline testing where applicable (CBC with differential, platelets, LFTs, electrolytes, BUN, creatinine, urinalysis).

    Denial Risk

    Incomplete documentation may delay or deny authorization

    Incomplete, incorrect, or illegible information on the request form or missing documentation supporting checked clinical criteria (labs, diagnostics, chart notes) can delay authorization or result in denial.

    Endocrinologist or other specified physician (to be documented)